Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 5,902 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mRI Clear all
Terminated Not applicable Interventional

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma

NCT04123535
View directory record Official record
Conditions
Undifferentiated Pleomorphic Sarcoma
Interventions
ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Device
Lead sponsor
Matthew Bucknor
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Medical Marijuana on Neurocognition and Escalation of Use

NCT03224468
View directory record Official record
Conditions
Pain, Insomnia, Depression, Anxiety
Interventions
Medical Marijuana
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 31, 2026, 10:12 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Validation of Presence-IP1.0 for Detection of Consciousness Using Reduced-Montage TMS-EEG

NCT07523191
View directory record Official record
Conditions
Sleep
Interventions
TMS combined with EEG, Presence-IP1.0
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

NCT05455697
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Interventions
Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin
Procedure · Drug · Biological + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Recruiting Phase 2 Interventional

Pilot fMRI Studies of Aging-Related Effects of THC

NCT06647524
View directory record Official record
Conditions
THC
Interventions
THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 31, 2026, 10:12 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320
View directory record Official record
Conditions
Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymus Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymus Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymus Neuroendocrine Neoplasm
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
432
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Not listed Not applicable Interventional

Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer

NCT01562223
View directory record Official record
Conditions
Prostate Cancer
Interventions
motexafin gadolinium
Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 31, 2026, 10:12 AM EDT
Completed Phase 3 Interventional

Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents

NCT00036582
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 10:12 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Advanced MR Imaging in Patients With Painful, Degenerative Disc Disease: A Pilot Study

NCT00706459
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Magnetic Resonance Imaging
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
25 Years to 60 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 31, 2026, 10:12 AM EDT
Completed Phase 2 Interventional

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

NCT01754935
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
VX-509, VX-509 matching placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Stanford, California • Upland, California • Fort Lauderdale, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 31, 2026, 10:12 AM EDT
Completed No phase listed Observational Results available

Sex and Obesity: Effects on Heart Failure Study

NCT00776035
View directory record Official record
Conditions
Obesity, Heart Failure
Interventions
PET (Positron Emission Tomography), Echocardiogram, ^15O-water, 1-^11C-palmitate, 1-^11C-glucose
Procedure · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
20 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 31, 2026, 10:12 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Cardiac Magnetic Resonance Imaging for Detecting Endothelial Dysfunction

NCT00808535
View directory record Official record
Conditions
Endothelial Dysfunction, Myocardial Perfusion Abnormalities, Cardiac MRI Perfusion With Vasomotor Stress, Diabetes
Interventions
Cardiac Perfusion MRI w Vasomotor Stress
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 31, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

NCT02611882
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 31, 2026, 10:12 AM EDT
Recruiting Phase 2 Interventional

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

NCT07110246
View directory record Official record
Conditions
BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Interventions
Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI), Specimen Collection, Optional Lumbar puncture
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Months to 25 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Active, not recruiting Early Phase 1 Interventional

Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis

NCT06233370
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Moderate intensity walking exercise
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Completed Not applicable Interventional

Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder

NCT01404273
View directory record Official record
Conditions
ADHD
Interventions
Meditation/Relaxation Response Training
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 49 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 31, 2026, 10:12 AM EDT
Not listed Not applicable Interventional

Molecular Imaging Assessment of ACL Viability

NCT03491046
View directory record Official record
Conditions
ACL Injury
Interventions
PET scan, MRI scan
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 31, 2026, 10:12 AM EDT
Recruiting Phase 2 Interventional

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

NCT07708961
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Temozolomide
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Touch and Attention MRI Study

NCT01432288
View directory record Official record
Conditions
Central Nervous System
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 31, 2026, 10:12 AM EDT
Recruiting Phase 2 Interventional

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT06499870
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix
Procedure · Drug · Other + 1 more
Lead sponsor
Sean Sachdev
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

NCT04025554
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 31, 2026, 10:12 AM EDT
Completed Not applicable Interventional

Axumin PETMRI Imaging Following Focal Cryo-ablation (FCA)

NCT04009083
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care MRI, Fluciclovine PET scan added to MRI
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 31, 2026, 10:12 AM EDT
Recruiting No phase listed Observational

Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke

NCT06615973
View directory record Official record
Conditions
Stroke, Brain Disease, Vascular Diseases, Cerebrovascular Disorder
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI

NCT03264456
View directory record Official record
Conditions
Prostate Cancer
Interventions
[18F] Fluciclovine PET/MRI, [18F] fluciclovine
Diagnostic Test · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 31, 2026, 10:12 AM EDT